文献速递其他结缔组织病

乌帕替尼治疗成人皮肌炎:中国队列研究

Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China.
PubMed 文献 · Semin Arthritis Rheum · 2026-08-07

该回顾性队列纳入40例接受乌帕替尼治疗的成人皮肌炎患者,随访6个月。3个月时VAS评分从基线3.93±1.75降至2.57±1.56(p<0.001),6个月进一步降至1.74±1.46(p<0.001);日均糖皮质激素剂量从基线29.03±17.02 mg分别降至17.66±10.35 mg和10.65±5.97 mg(均p<0.001)。仅4例抗MDA5抗体阳性患者出现病情加重或复发,感染是最常见并发症(17例)。

要点

  • 乌帕替尼治疗3个月和6个月时VAS评分及日均激素剂量均显著下降。
  • 皮肤受累、间质性肺病和MMT8评分在3个月时显著改善。
  • 感染最常见(17例),包括6例CMV病毒血症和3例带状疱疹。

核心结论

  • 乌帕替尼可能为成人皮肌炎的有前景治疗选择,有助于临床改善和减少糖皮质激素剂量。

研究设计与样本

  • 回顾性研究纳入2024年1月至2025年4月接受乌帕替尼治疗的40例成人皮肌炎患者,随访6个月,收集临床数据和并发症。

主要发现

  • 40例患者中21例(52.5%)为女性,平均年龄46.93±11.04岁,中位病程14(8.25,31)个月。
  • 基线平均疾病VAS评分为3.93±1.75,日均GC剂量为29.03±17.02 mg。
  • 3个月随访时平均VAS评分降至2.57±1.56(p<0.001),皮肤受累、间质性肺病和MMT8评分均显著改善(均p<0.05),日均GC剂量降至17.66±10.35 mg(p<0.001)。
  • 6个月时平均VAS评分进一步降至1.74±1.46(p<0.001),日均GC剂量进一步降至10.65±5.97 mg(p<0.001)。
  • 仅4例抗MDA5抗体阳性患者出现病情加重或复发;感染最常见(17例),包括6例CMV病毒血症和3例带状疱疹。

临床怎么用

  • 在成人皮肌炎患者中,乌帕替尼治疗可考虑用于临床改善和减少糖皮质激素剂量,但需监测感染(包括CMV病毒血症和带状疱疹)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This retrospective study investigated the efficacy and safety of upadacitinib in adult patients with dermatomyositis (DM). METHODS: Adult patients with DM who received upadacitinib between January 2024 and April 2025 were included and followed up for 6 months. Clinical data and complications were collected. RESULTS: The cohort included 40 adult patients with DM, of whom 21 (52.5%) were female. The mean age was 46.93 ± 11.04 years. The median disease duration was 14 (8.25, 31) months. At baseline, the mean disease visual analog scale (VAS) score was 3.93 ± 1.75, and the mean daily glucocorticoid (GC) dose was 29.03 ± 17.02 mg. By the 3-month follow-up, the mean VAS score decreased to 2.57 ± 1.56 (p < 0.001), with significant improvements in cutaneous involvement, interstitial lung disease and manual muscle test 8 score (all p < 0.05). The mean daily GC dose was reduced to 17.66 ± 10.35 mg (p < 0.001). At 6 months, the mean VAS score further decreased to 1.74 ± 1.46 (p < 0.001). The mean daily GC dose was further reduced to 10.65 ± 5.97 mg (p < 0.001). Only four patients with anti-MDA5 antibody showed disease aggravation or relapsed in the cohort. Infection was the most common complication affecting 17 patients, including 6 patients with CMV viraemia and 3 patients with herpes zoster. CONCLUSION: Upadacitinib may be a promising treatment option for adult DM, contributing to clinical improvement and GC dose reduction.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Shanshan L, Xiaoxing W, Haiyan L, et al. Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China. Semin Arthritis Rheum. 2026. PMID: 42579998. doi:10.1016/j.semarthrit.2026.153054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。